BE2016C056I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C056I2
Authority: BE; Belgium
Prior art keywords: antagonists; subject; present disclosure; disclosure; neutralize
Prior art date: 2003-05-08

Application number

BE2016C056C

Other languages

English (en)

Original Assignee

Abbvie Biotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-08

Filing date

2016-10-24

Publication date

2023-08-09

2016-10-24 Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc

2023-08-09 Publication of BE2016C056I2 publication Critical patent/BE2016C056I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Glass Compositions (AREA)
Luminescent Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BE2016C056C 2003-05-08 2016-10-24 BE2016C056I2 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US46921103P	2003-05-08	2003-05-08
US55762004P	2004-03-29	2004-03-29
US55762104P	2004-03-29	2004-03-29
US55762204P	2004-03-29	2004-03-29
EP04760993A EP1624892B1 (fr)	2003-05-08	2004-05-10	Utilisation therapeutique d'anticorps anti-cs1

Publications (1)

Publication Number	Publication Date
BE2016C056I2 true BE2016C056I2 (fr)	2023-08-09

Family

ID=33459144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C056C BE2016C056I2 (fr)	2003-05-08	2016-10-24

Country Status (25)

Country	Link
US (8)	US20050025763A1 (fr)
EP (4)	EP1624892B1 (fr)
JP (4)	JP4887152B2 (fr)
KR (1)	KR101268707B1 (fr)
CN (1)	CN1805755B (fr)
AT (1)	ATE506076T1 (fr)
AU (2)	AU2004238363B2 (fr)
BE (1)	BE2016C056I2 (fr)
BR (1)	BRPI0410129B8 (fr)
CA (1)	CA2523001C (fr)
CY (4)	CY1111958T1 (fr)
DE (1)	DE602004032328D1 (fr)
DK (3)	DK2853272T3 (fr)
ES (2)	ES2643289T3 (fr)
FR (1)	FR16C1012I2 (fr)
HK (1)	HK1208815A1 (fr)
HU (2)	HUE034908T2 (fr)
LT (1)	LT2853272T (fr)
LU (1)	LU93274I2 (fr)
MX (1)	MXPA05012011A (fr)
NL (1)	NL300838I2 (fr)
PL (3)	PL2371391T3 (fr)
PT (3)	PT1624892E (fr)
SI (3)	SI2853272T1 (fr)
WO (1)	WO2004100898A2 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) *	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US20080095768A1 (en) *	2006-08-07	2008-04-24	Pdl Biopharma, Inc.	Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
US8632772B2 (en) *	2006-08-07	2014-01-21	Dana-Farber Cancer Institute	Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
NZ574979A (en) *	2006-08-07	2012-06-29	Abbott Biotherapeutics Corp	Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
EP3384919A1 (fr)	2008-06-02	2018-10-10	Dana Farber Cancer Institute, Inc.	Peptides cs1
EP2361263A1 (fr) *	2008-10-31	2011-08-31	Abbott Biotherapeutics Corp.	Utilisation d anticorps anti-cs1 pour le traitement des lymphomes rares
EP2382321A4 (fr) *	2009-01-08	2012-12-19	Bio Rad Laboratories	Procédés et compositions pour améliorer l'efficacité de réactions d'amplification d'acides nucléiques
US20120269814A1 (en) *	2009-11-10	2012-10-25	Amgen Inc.	Anti-c mpl antibodies
EP2528947A4 (fr) *	2010-01-28	2013-09-18	Glaxo Group Ltd	Protéines de liaison à cd127
CA3014767C (fr)	2010-02-24	2023-08-29	Immunogen, Inc.	Anticorps du recepteur 1 du folate et immunoconjugues et leurs utilisations
MX346555B (es)	2011-04-01	2017-03-24	Immunogen Inc	Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
SG11201500938XA (en)	2012-08-31	2015-04-29	Immunogen Inc	Diagnostic assays and kits for detection of folate receptor 1
US9950047B2 (en)	2012-11-05	2018-04-24	Dana-Farber Cancer Institute, Inc.	XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
JP6449229B2 (ja) *	2013-03-15	2019-01-09	アッヴィ・バイオセラピューティクス・インコーポレイテッド	Ｆｃ変異体
HK1220470A1 (zh) *	2013-03-15	2017-05-05	Abbvie Biotechnology Ltd.	抗cd25抗体及其用途
BR112015027567B1 (pt) *	2013-05-03	2024-02-20	Ohio State Innovation Foundation	Polipeptídeo, sequência de ácido nucleico isolada, vetor, método de obtenção de célula, uso de uma célula
WO2015013508A2 (fr) *	2013-07-24	2015-01-29	The General Hospital Corporation	Procédés permettant de diagnostiquer et de traiter une maladie du système immunitaire
MX371496B (es)	2013-08-30	2020-01-31	Immunogen Inc	Anticuerpos y ensayos para la detección del receptor 1 de folato.
US9482289B2 (en)	2013-10-14	2016-11-01	Club Car, Llc	Self-preloading shift lever
ES2707057T3 (es)	2013-11-06	2019-04-02	Bristol Myers Squibb Co	Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
WO2015069703A1 (fr)	2013-11-06	2015-05-14	Bristol-Myers Squibb Company	Schémas posologiques immunothérapeutiques et combinaisons de ceux-ci
EP3524616A1 (fr) *	2014-05-02	2019-08-14	Cellectis	Récepteur antigénique chimérique à chaînes multiples spécifique de cs1
US20170129955A1 (en) *	2014-06-17	2017-05-11	The Regents Of The University Of California	Alpha-v beta-8 antibodies
CA2954414A1 (fr)	2014-07-15	2016-01-21	Juno Therapeutics, Inc.	Cellules modifiees pour therapie cellulaire adoptive
WO2016049022A1 (fr) *	2014-09-23	2016-03-31	Board Of Trustees Of Michigan State University	Compositions et procédés de modulation d'une réponse immunitaire
JP2017537893A (ja) *	2014-10-31	2017-12-21	アッヴィ・バイオセラピューティクス・インコーポレイテッド	抗ｃｓ１抗体および抗体薬結合体
MX2017007097A (es)	2014-12-04	2017-09-05	Bristol Myers Squibb Co	Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
DE102015102183B4 (de) *	2015-02-16	2018-03-01	Robert Bosch Automotive Steering Gmbh	Lenkzwischenwelle für ein Kraftfahrzeug und Verfahren zum Betreiben einer Lenkzwischenwelle für ein Kraftfahrzeug
WO2016134371A2 (fr)	2015-02-20	2016-08-25	Ohio State Innovation Foundation	Anticorps bivalent dirigé contre nkg2d et antigènes associés à une tumeur
US20180100026A1 (en) *	2015-04-15	2018-04-12	California Institute For Biomedical Research	Optimized chimeric receptor t cell switches and uses thereof
CA2990478A1 (fr)	2015-06-29	2017-01-05	Bristol-Myers Squibb Company	Schemas posologiques immunotherapeutiques a base de pomalidomide et d'un anticorps anti-cs1 pour le traitement du cancer
MA42895A (fr)	2015-07-15	2018-05-23	Juno Therapeutics Inc	Cellules modifiées pour thérapie cellulaire adoptive
CN108601828B (zh)	2015-09-17	2023-04-28	伊缪诺金公司	包含抗folr1免疫缀合物的治疗组合
LT3370768T (lt)	2015-11-03	2022-05-25	Janssen Biotech, Inc.	Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
CN110636857B (zh) *	2017-03-13	2024-04-30	因全惜客生命科学有限公司	人红富铁激素的抗体及其用途
CN110382546B (zh) *	2017-03-29	2024-08-09	新加坡科技研究局	抗寡糖抗体
CN114058590B (zh)	2017-06-20	2024-08-06	居里研究所	Suv39h1缺陷的免疫细胞
KR102486090B1 (ko)	2017-08-07	2023-01-10	엔비이-테라퓨틱스 아게	생체 내 내성이 높은 항체 약물 결합체
PT3703750T (pt)	2017-11-01	2025-01-17	Memorial Sloan Kettering Cancer Center	Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
US20210254000A1 (en)	2017-11-01	2021-08-19	Juno Therapeutics, Inc.	Process for producing a t cell composition
EP3704230B1 (fr)	2017-11-01	2024-10-23	Juno Therapeutics, Inc.	Procédé de génération de compositions thérapeutiques de cellules modifiées
US11564946B2 (en)	2017-11-01	2023-01-31	Juno Therapeutics, Inc.	Methods associated with tumor burden for assessing response to a cell therapy
WO2019089858A2 (fr)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
CN111511370A (zh)	2017-11-01	2020-08-07	朱诺治疗学股份有限公司	对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
MX2020005907A (es)	2017-12-08	2020-10-19	Juno Therapeutics Inc	Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
AU2018379094B2 (en)	2017-12-08	2025-09-25	Juno Therapeutics, Inc.	Phenotypic markers for cell therapy and related methods
BR112020011215A2 (pt)	2017-12-08	2020-11-17	Juno Therapeutics Inc	processo para a produção de uma composição de células t modificadas
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3093200A1 (fr)	2018-03-05	2019-09-12	Janssen Pharmaceutica Nv	Anticorps anti-phf-tau et leurs utilisations
WO2020002592A1 (fr)	2018-06-29	2020-01-02	Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis	Inhibiteurs de traf2 destinés à être utilisés dans le traitement d'un cancer
AU2019316647A1 (en)	2018-08-09	2021-02-25	Juno Therapeutics, Inc.	Methods for assessing integrated nucleic acids
CN109406798A (zh) *	2018-10-29	2019-03-01	美康生物科技股份有限公司	肌酐酶法检测试剂盒
EP3873943A2 (fr)	2018-11-01	2021-09-08	Juno Therapeutics, Inc.	Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
JP7742773B2 (ja)	2018-11-01	2025-09-22	ジュノーセラピューティクスインコーポレイテッド	Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
IL263394A (en) *	2018-11-29	2020-05-31	Amit Ido	Methods of activating dysfunctional immune cells and treatment of cancer
US20220184131A1 (en)	2019-05-01	2022-06-16	Juno Therapeutics, Inc.	Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
BR112021021200A2 (pt)	2019-05-01	2021-12-21	Juno Therapeutics Inc	Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
BR112022001148A2 (pt)	2019-07-23	2022-03-15	Inst Nat Sante Rech Med	Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
US20220390455A1 (en)	2019-11-05	2022-12-08	Bristol-Myers Squibb Company	M-protein assays and uses thereof
KR20220137696A (ko) *	2020-02-05	2022-10-12	나보, 인크.	항-헵신 항체 및 그의 용도
CN115916223A (zh)	2020-04-10	2023-04-04	朱诺治疗学股份有限公司	与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
CN115803824A (zh)	2020-05-13	2023-03-14	朱诺治疗学股份有限公司	鉴定与临床反应相关的特征的方法及其用途
CN116234558A (zh)	2020-06-26	2023-06-06	朱诺治疗学有限公司	条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
WO2022023576A1 (fr)	2020-07-30	2022-02-03	Institut Curie	Cellules immunitaires défectives en socs1
WO2022031602A1 (fr) *	2020-08-06	2022-02-10	Promab Biotechnologies, Inc.	Anticorps cs1 et lymphocytes car-t anti-cs1
EP4240756A1 (fr)	2020-11-04	2023-09-13	Juno Therapeutics, Inc.	Cellules exprimant un récepteur chimérique à partir d'un locus de chaîne de la superfamille des immunoglobines cd3 invariable modifié, polynucléotides et procédés associés
KR20230165771A (ko)	2021-03-03	2023-12-05	주노 쎄러퓨티크스 인코퍼레이티드	T 세포 요법 및 dgk 억제제의 조합
KR20240018454A (ko)	2021-05-06	2024-02-13	주노 테라퓨틱스 게엠베하	T 세포의 자극 및 형질도입 방법
EP4337763A1 (fr)	2021-05-10	2024-03-20	Institut Curie	Procédés de traitement du cancer, de maladies inflammatoires et de maladies auto-immunes
WO2022248602A1 (fr)	2021-05-25	2022-12-01	Institut Curie	Cellules myéloïdes surexprimant bcl2
JP2025501272A (ja)	2021-12-28	2025-01-17	ムネモ・セラピューティクス	不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
US20250101379A1 (en)	2022-01-28	2025-03-27	Juno Therapeutics, Inc.	Methods of manufacturing cellular compositions
MX2024010003A (es)	2022-02-18	2024-09-30	Rakuten Medical Inc	Moléculas de anticuerpo anti-ligando 1 de muerte programada (pd-l1), polinucleótidos que las codifican y métodos de uso.
US20250213614A1 (en)	2022-03-31	2025-07-03	Institut Curie	Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression
WO2023213969A1 (fr)	2022-05-05	2023-11-09	Juno Therapeutics Gmbh	Protéine de liaison virale et réactifs, articles et méthodes d'utilisation associés
WO2023220655A1 (fr)	2022-05-11	2023-11-16	Celgene Corporation	Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
EP4532695A1 (fr)	2022-05-25	2025-04-09	Celgene Corporation	Procédés de fabrication de thérapies par lymphocytes t
WO2023230548A1 (fr)	2022-05-25	2023-11-30	Celgene Corporation	Procédé de prédiction d'une réponse à une thérapie par lymphocyte t
CN115141825A (zh) *	2022-08-12	2022-10-04	武汉希望组生物科技有限公司	一种微小型昆虫基因组dna的提取方法
KR20250061756A (ko)	2022-09-08	2025-05-08	주노 쎄러퓨티크스 인코퍼레이티드	T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
EP4615960A1 (fr)	2022-11-09	2025-09-17	C3S2 GmbH	Procédés de fabrication de cellules immunitaires modifiées
EP4626924A1 (fr) *	2022-12-02	2025-10-08	Guangzhou Litai Biotechnology Co., Ltd.	Lymphocytes t-car cs1 humains
KR20250121074A (ko)	2022-12-09	2025-08-11	주노 쎄러퓨티크스 인코퍼레이티드	홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
EP4658675A1 (fr)	2023-02-03	2025-12-10	C3S2 GmbH	Procédés de fabrication non virale de cellules immunitaires modifiées
US20260001951A1 (en)	2024-06-28	2026-01-01	Immunitybio, Inc.	Anti-SLAMF7 Antibodies And Therapeutics

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
CH652145A5 (de)	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en)	1984-01-06	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Human-murine hybridoma fusion partner
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en)	1985-03-15	1993-08-10	Anti-Gene Development Group	Alpha-morpholino ribonucleoside derivatives and polymers thereof
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (fr)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Procede pour ameliorer la stabilite des glycoproteines
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en)	1987-12-15	1991-04-02	Protein Design Labs, Inc.	Cloning and expression of phosopholipase C genes
US5700637A (en)	1988-05-03	1997-12-23	Isis Innovation Limited	Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en)	1989-09-07	2001-12-11	Alkermes, Inc.	Transferrin receptor reactive chimeric antibodies
KR0162259B1 (ko)	1989-12-05	1998-12-01	아미 펙터	감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
US20020099179A1 (en) *	1989-12-21	2002-07-25	Linda K. Jolliffe	Cdr-grafted antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
US5386023A (en)	1990-07-27	1995-01-31	Isis Pharmaceuticals	Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
WO1993012227A1 (fr)	1991-12-17	1993-06-24	Genpharm International, Inc.	Animaux transgeniques non humains capables de produire des anticorps heterologues
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5644048A (en)	1992-01-10	1997-07-01	Isis Pharmaceuticals, Inc.	Process for preparing phosphorothioate oligonucleotides
JPH07101999A (ja) *	1993-10-06	1995-04-18	Hagiwara Yoshihide	抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US5637684A (en)	1994-02-23	1997-06-10	Isis Pharmaceuticals, Inc.	Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en)	1994-03-16	2000-01-18	California Institute Of Technology	Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en)	1994-06-17	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods for fabricating microarrays of biological samples
AU6094696A (en)	1995-06-05	1996-12-24	Bionebraska, Inc.	Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) *	1996-03-26	2003-08-19	Oncomedx, Inc.	Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
CA2284550A1 (fr)	1997-03-21	1998-10-01	Human Genome Sciences, Inc.	87 proteines humaines secretees
IL139686A0 (en)	1998-06-02	2002-02-10	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6020599A (en)	1998-08-25	2000-03-14	Incyte Pharmaceuticals, Inc.	Cell surface immunomodulators
US20030187196A1 (en) *	1998-12-30	2003-10-02	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1159284A4 (fr)	1999-02-10	2003-10-29	Human Genome Sciences Inc	33 proteines humaines secretees
CA2296792A1 (fr)	1999-02-26	2000-08-26	Genset S.A.	Sequences marqueurs exprimees et proteines humaines codees
AU3750000A (en)	1999-03-15	2000-10-04	Eos Biotechnology, Inc.	Reusable low fluorescent plastic biochip
CA2383254A1 (fr)	1999-06-02	2000-12-07	Genentech, Inc.	Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
JP3951035B2 (ja)	1999-09-01	2007-08-01	ジェネンテック・インコーポレーテッド	分泌及び膜貫通ポリペプチドとそれをコードしている核酸
WO2001046260A2 (fr) *	1999-12-23	2001-06-28	Bristol-Myers Squibb Company	Nouveaux membres de la superfamille des immunoglobulines apex-1, apex-2 et apex-3 et leurs utilisations
AU6802801A (en)	2000-03-01	2001-09-24	Genentech Inc	Secreted and transmembrane polypeptides and nucleic acids encoding the same
CZ20023203A3 (cs) *	2000-03-24	2003-08-13	Micromet Ag	Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D
US20030215450A1 (en)	2000-05-26	2003-11-20	Blake Simon M	Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6410271B1 (en)	2000-06-23	2002-06-25	Genetastix Corporation	Generation of highly diverse library of expression vectors via homologous recombination in yeast
KR20030091978A (ko) *	2001-01-29	2003-12-03	아이덱 파마슈티칼즈 코포레이션	변형된 항체 및 사용 방법
WO2003038063A2 (fr)	2001-03-21	2003-05-08	Human Genome Sciences, Inc.	Proteines secretees humaines
US20030099974A1 (en) *	2001-07-18	2003-05-29	Millennium Pharmaceuticals, Inc.	Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002313559A1 (en)	2001-08-23	2003-03-10	Oxford Biomedica (Uk) Limited	Genes
US20040038877A1 (en)	2001-10-02	2004-02-26	Alsobrook John P.	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) *	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
US6478825B1 (en) *	2001-11-28	2002-11-12	Osteotech, Inc.	Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) *	2001-12-12	2006-05-09	University Of North Texas Health Science Center	Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
WO2004029207A2 (fr)	2002-09-27	2004-04-08	Xencor Inc.	Variants fc optimises et methodes destinees a leur generation
US7709610B2 (en) *	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
EP2361263A1 (fr)	2008-10-31	2011-08-31	Abbott Biotherapeutics Corp.	Utilisation d anticorps anti-cs1 pour le traitement des lymphomes rares
CN104010774B (zh)	2011-09-15	2017-10-13	康富真信息技术股份有限公司	用于自动生成机器人程序的系统和方法
CA2866478C (fr)	2012-02-13	2019-07-23	Radius Engineering Inc.	Cartouche reutilisable pour le moulage par injection

2004
- 2004-05-07 US US10/842,011 patent/US20050025763A1/en not_active Abandoned
- 2004-05-10 BR BRPI0410129A patent/BRPI0410129B8/pt active IP Right Grant
- 2004-05-10 DE DE602004032328T patent/DE602004032328D1/de not_active Expired - Lifetime
- 2004-05-10 CN CN2004800164542A patent/CN1805755B/zh not_active Expired - Lifetime
- 2004-05-10 DK DK14178061.9T patent/DK2853272T3/da active
- 2004-05-10 EP EP04760993A patent/EP1624892B1/fr not_active Expired - Lifetime
- 2004-05-10 AT AT04760993T patent/ATE506076T1/de active
- 2004-05-10 SI SI200432408T patent/SI2853272T1/sl unknown
- 2004-05-10 PT PT04760993T patent/PT1624892E/pt unknown
- 2004-05-10 PL PL10183377T patent/PL2371391T3/pl unknown
- 2004-05-10 SI SI200432193T patent/SI2371391T1/sl unknown
- 2004-05-10 DK DK10183377.0T patent/DK2371391T3/da active
- 2004-05-10 PL PL04760993T patent/PL1624892T3/pl unknown
- 2004-05-10 MX MXPA05012011A patent/MXPA05012011A/es active IP Right Grant
- 2004-05-10 EP EP14178061.9A patent/EP2853272B1/fr not_active Expired - Lifetime
- 2004-05-10 PT PT141780619T patent/PT2853272T/pt unknown
- 2004-05-10 PT PT101833770T patent/PT2371391E/pt unknown
- 2004-05-10 LT LTEP14178061.9T patent/LT2853272T/lt unknown
- 2004-05-10 SI SI200431707T patent/SI1624892T1/sl unknown
- 2004-05-10 AU AU2004238363A patent/AU2004238363B2/en not_active Expired
- 2004-05-10 WO PCT/US2004/014866 patent/WO2004100898A2/fr not_active Ceased
- 2004-05-10 ES ES14178061.9T patent/ES2643289T3/es not_active Expired - Lifetime
- 2004-05-10 ES ES10183377.0T patent/ES2516840T3/es not_active Expired - Lifetime
- 2004-05-10 EP EP17176948.2A patent/EP3275463A1/fr not_active Withdrawn
- 2004-05-10 JP JP2006532992A patent/JP4887152B2/ja not_active Expired - Lifetime
- 2004-05-10 PL PL14178061T patent/PL2853272T3/pl unknown
- 2004-05-10 HU HUE14178061A patent/HUE034908T2/hu unknown
- 2004-05-10 DK DK04760993.8T patent/DK1624892T3/da active
- 2004-05-10 CA CA2523001A patent/CA2523001C/fr not_active Expired - Lifetime
- 2004-05-10 EP EP10183377.0A patent/EP2371391B1/fr not_active Expired - Lifetime
2005
- 2005-11-07 KR KR1020057021141A patent/KR101268707B1/ko not_active Expired - Lifetime
2009
- 2009-03-10 US US12/401,531 patent/US20090238827A1/en not_active Abandoned
- 2009-03-10 US US12/401,513 patent/US8133981B2/en not_active Expired - Lifetime
- 2009-11-02 US US12/610,899 patent/US8008450B2/en not_active Expired - Lifetime
2010
- 2010-08-25 AU AU2010214661A patent/AU2010214661B2/en not_active Expired
2011
- 2011-06-30 US US13/174,134 patent/US8445646B2/en not_active Expired - Fee Related
- 2011-07-14 CY CY20111100687T patent/CY1111958T1/el unknown
- 2011-09-22 JP JP2011207654A patent/JP5976288B2/ja not_active Expired - Lifetime
2013
- 2013-05-15 US US13/894,857 patent/US9175081B2/en not_active Expired - Lifetime
2014
- 2014-02-20 JP JP2014030549A patent/JP6042834B2/ja not_active Expired - Lifetime
- 2014-10-23 CY CY20141100872T patent/CY1115671T1/el unknown
2015
- 2015-09-22 US US14/860,906 patent/US10442859B2/en not_active Expired - Lifetime
- 2015-09-29 HK HK15109572.0A patent/HK1208815A1/en unknown
2016
- 2016-07-20 JP JP2016142300A patent/JP2017019795A/ja active Pending
- 2016-10-20 HU HUS1600042C patent/HUS1600042I1/hu unknown
- 2016-10-24 BE BE2016C056C patent/BE2016C056I2/fr unknown
- 2016-10-24 LU LU93274C patent/LU93274I2/fr unknown
- 2016-10-25 NL NL300838C patent/NL300838I2/nl unknown
- 2016-10-26 CY CY2016035C patent/CY2016035I1/el unknown
- 2016-10-27 FR FR16C1012C patent/FR16C1012I2/fr active Active
2017
- 2017-09-15 CY CY20171100980T patent/CY1119353T1/el unknown
2019
- 2019-10-10 US US16/599,035 patent/US20200031929A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1805755A (zh)	2006-07-19
DK1624892T3 (da)	2011-08-08
HK1089374A1 (en)	2006-12-01
CY1115671T1 (el)	2017-01-25
US20090238827A1 (en)	2009-09-24
JP2007503465A (ja)	2007-02-22
AU2010214661B2 (en)	2012-05-17
CA2523001A1 (fr)	2004-11-25
AU2010214661A1 (en)	2010-09-16
CN1805755B (zh)	2011-06-01
JP2014139187A (ja)	2014-07-31
US10442859B2 (en)	2019-10-15
PL1624892T3 (pl)	2011-09-30
JP6042834B2 (ja)	2016-12-14
EP1624892A4 (fr)	2007-08-08
SI1624892T1 (sl)	2011-08-31
US20120064083A1 (en)	2012-03-15
US20100168397A1 (en)	2010-07-01
WO2004100898A3 (fr)	2005-08-18
SI2853272T1 (sl)	2017-10-30
US8445646B2 (en)	2013-05-21
FR16C1012I1 (fr)	2016-09-12
NL300838I2 (fr)	2017-01-03
HK1208815A1 (en)	2016-03-18
MXPA05012011A (es)	2006-02-03
EP2371391A1 (fr)	2011-10-05
CY2016035I2 (el)	2017-09-13
EP2853272A1 (fr)	2015-04-01
DE602004032328D1 (de)	2011-06-01
BRPI0410129A (pt)	2006-05-16
KR101268707B1 (ko)	2013-05-29
US8133981B2 (en)	2012-03-13
LT2853272T (lt)	2017-10-10
US20200031929A1 (en)	2020-01-30
EP3275463A1 (fr)	2018-01-31
WO2004100898A2 (fr)	2004-11-25
HUE034908T2 (hu)	2018-03-28
PT2371391E (pt)	2014-10-30
US20140065063A1 (en)	2014-03-06
CA2523001C (fr)	2013-12-31
FR16C1012I2 (fr)	2019-01-11
ES2643289T3 (es)	2017-11-22
AU2004238363A1 (en)	2004-11-25
BRPI0410129B8 (pt)	2021-05-25
EP2853272B1 (fr)	2017-08-02
CY1111958T1 (el)	2015-11-04
BRPI0410129B1 (pt)	2020-02-11
LU93274I2 (fr)	2016-12-27
AU2004238363B2 (en)	2010-05-27
US20160002335A1 (en)	2016-01-07
JP4887152B2 (ja)	2012-02-29
US8008450B2 (en)	2011-08-30
EP1624892B1 (fr)	2011-04-20
JP2017019795A (ja)	2017-01-26
CY1119353T1 (el)	2018-02-14
PT2853272T (pt)	2017-08-30
ATE506076T1 (de)	2011-05-15
ES2516840T3 (es)	2014-10-31
HUS1600042I1 (hu)	2016-11-28
PL2371391T3 (pl)	2015-01-30
DK2853272T3 (da)	2017-11-06
US20050025763A1 (en)	2005-02-03
PT1624892E (pt)	2011-07-12
HK1163497A1 (en)	2012-09-14
KR20060018837A (ko)	2006-03-02
EP2371391B1 (fr)	2014-07-23
DK2371391T3 (da)	2014-11-03
US9175081B2 (en)	2015-11-03
JP5976288B2 (ja)	2016-08-23
JP2012121878A (ja)	2012-06-28
US20090238835A1 (en)	2009-09-24
SI2371391T1 (sl)	2014-12-31
CY2016035I1 (el)	2017-09-13
PL2853272T3 (pl)	2018-01-31
EP1624892A2 (fr)	2006-02-15

Publication	Publication Date	Title
NL300838I2 (fr)	2017-01-03
DE602004029399D1 (fr)	2010-11-11
BRPI0413489A (pt)	2006-10-17	composições polipeptìdicas de ligação a cd20
KR101155294B1 (ko)	2013-03-07	면역특이적으로 ＢＬｙＳ에 결합하는 항체
MXPA06003788A (es)	2006-06-14	Anticuerpos completamente humanos contra 4-1bb humano (cd137).
ATE470676T1 (de)	2010-06-15	Anti-vegf-2 antikörper
UA89350C2 (uk)	2010-01-25	Гуманізоване антитіло, що зв'язує людський cd20
WO2006138729A3 (fr)	2009-02-12	Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2006002177A3 (fr)	2006-06-22	Anticorps anti-recepteur aux interferons alpha 1 et leurs utilisations
WO2002074251A3 (fr)	2004-02-19	Traitement par anticorps monoclonal du cancer du pancreas
CY1115003T1 (el)	2016-12-14	Θεραπευτικη χρηση των αντισωματων αντι-cs1
WO2003097082A3 (fr)	2004-12-09	Traitement de la maladie de crohn ou du psoriasis a partir d'anticorps anti-interferon gamma
WO2005014653A3 (fr)	2005-06-16	Anticorps de poulet humanises
WO2001090361A3 (fr)	2002-08-08	Modulation des effets de protease sur des substrats de chimiokines
UA91182C2 (ru)	2010-07-12	Антитело, которое специфично связывается с фактором роста соединительной ткани (ctgf)